Document Detail


Costs and outcomes of noncardioembolic ischemic stroke in a managed care population.
MedLine Citation:
PMID:  20957133     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To evaluate the clinical outcomes and incremental health care costs of ischemic stroke in a US managed care population.
PATIENTS AND METHODS: A retrospective cohort analysis was done on patients (aged 18+ years) hospitalized with noncardioembolic ischemic stroke from January 1, 2002, through December 31, 2003, identified from commercial health plan administrative claims. New or recurrent stroke was based on history in the previous 12 months, with index date defined as first date of indication of stroke. A control group without stroke or transient ischemic attack (TIA) was matched (1:3) on age, sex, and geographic region, with an index date defined as the first medical claim during the patient identification period. Patients with atrial fibrillation or mitral value abnormalities were excluded. Ischemic stroke and control cohorts were compared on 4-year clinical outcomes and 1-year costs.
RESULTS: Of 2180 ischemic stroke patients, 1808 (82.9%) had new stroke and 372 (17.1%) had a recurrent stroke. Stroke patients had higher unadjusted rates of additional stroke, TIA, and fatal outcomes compared with the 6540 matched controls. Recurrent stroke patients had higher rates of adverse clinical outcomes compared with new stroke patients; costs attributed to recurrent stroke were also higher. Stroke patients were 2.4 times more likely to be hospitalized in follow-up compared with controls (hazard ratio [HR] 2.4, 95% confidence interval [CI]: 2.2, 2.6). Occurrence of stroke following discharge was 21 times more likely among patients with index stroke compared with controls (HR 21.0, 95% CI: 16.1, 27.3). Stroke was also predictive of death (HR 1.8, 95% CI: 1.3, 2.5). Controlling for covariates, stroke patients had significantly higher costs compared with control patients in the year following the index event.
CONCLUSION: Noncardioembolic ischemic stroke patients had significantly poorer outcomes and higher costs compared with controls. Recurrent stroke appears to contribute substantially to these higher rates of adverse outcomes and costs.
Authors:
Nicole M Engel-Nitz; Stephen D Sander; Carolyn Harley; Gabriel Gomez Rey; Hemal Shah
Related Documents :
18272283 - Hemodynamic blood flow disturbances in the middle cerebral arteries in patients with at...
3965773 - Factors influencing return to work following cerebral infarction.
19100953 - Low serum 25 (oh) vitamin d levels (<32 ng/ml) are associated with reversible myositis-...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-05
Journal Detail:
Title:  Vascular health and risk management     Volume:  6     ISSN:  1178-2048     ISO Abbreviation:  Vasc Health Risk Manag     Publication Date:  2010  
Date Detail:
Created Date:  2010-10-19     Completed Date:  2010-12-03     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  101273479     Medline TA:  Vasc Health Risk Manag     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  905-13     Citation Subset:  IM    
Affiliation:
Health Economic and Outcomes Research, i3 Innovus, Eden Prairie, MN, USA. nicole.engel-nitz@i3innovus.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Age Factors
Aged
Chi-Square Distribution
Female
Health Care Costs*
Hospitalization / economics
Humans
Kaplan-Meier Estimate
Male
Managed Care Programs / economics*
Middle Aged
Outcome and Process Assessment (Health Care) / economics*
Proportional Hazards Models
Retrospective Studies
Stroke / economics*
United States
Young Adult
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New class of agents for treatment of hypertension: focus on direct renin inhibition.
Next Document:  Role of tipranavir in treatment of patients with multidrug-resistant HIV.